    [
        {
            "ID": "1",
            "DrugID": "001",
            "Drug": "Aprepitant",
            "Route": "Oral",
            "Website": "http://www.pbs.gov.au/pbs/search?term=Aprepitant&search-type=medicines&analyse=false",
            "Details": [
                {
                    "DetailID": "001a",
                    "Strength": "165mg",
                    "PBSCode": "2518M",
                    "Streamline": "4211",
                    "PBSQty": "1",
                    "PBSRepeats": "5",
                    "Category": "GE",
                    "Restriction": "A",
                    "Type": "General",
                    "ScriptType": "Streamline Authority",
                    "Diagnosis": "Nausea and vomiting (with cytotoxic chemotherapy)",
                    "Treatment": "",
                    "Criteria": "The condition must be associated with cytotoxic chemotherapy being used to treat malignancy, AND The treatment must be in combination with a 5-hydroxytryptamine receptor (5HT3) antagonist and dexamethasone, AND Patient must be scheduled to be administered a chemotherapy regimen that includes any 1 of the following agents: altretamine; carmustine; cisplatin when a single dose constitutes a cycle of chemotherapy; cyclophosphamide at a dose of 1500 mg per square metre per day or greater; dacarbazine; procarbazine when a single dose constitutes a cycle of chemotherapy; streptozocin. No more than 1 capsule of aprepitant 165 mg will be authorised per cycle of cytotoxic chemotherapy."
                },
                {
                    "DetailID": "001b",
                    "PBSCode": "2518M",
                    "Streamline": "4213",
                    "PBSQty": "1",
                    "PBSRepeats": "5",
                    "Category": "GE",
                    "Restriction": "A",
                    "Type": "General",
                    "ScriptType": "Streamline Authority",
                    "Diagnosis": "Nausea and vomiting (breast cancer)",
                    "Treatment": "",
                    "Criteria": "The condition must be associated with moderately emetogenic cytotoxic chemotherapy being used to treat malignancy, AND The treatment must be in combination with a 5-hydroxytryptamine receptor (5HT3) antagonist and dexamethasone on day 1 of a chemotherapy cycle, AND Patient must have had a prior episode of chemotherapy induced nausea or vomiting, AND Patient must be scheduled to be administered a chemotherapy regimen that includes any 1 of the following intravenous chemotherapy agents: arsenic trioxide; azacitidine; carboplatin; cyclophosphamide at a dose of less than 1500 mg per square metre per day; cytarabine at a dose of greater than 1 g per square metre per day; dactinomycin; daunorubicin; doxorubicin; epirubicin; fotemustine; idarubicin; ifosfamide; irinotecan; melphalan; methotrexate at a dose of 250 mg to 1 g per square metre; oxaliplatin; raltitrexed. No more than 1 capsule of aprepitant 165 mg will be authorised per cycle of cytotoxic chemotherapy. Concomitant use of a 5HT3 antagonist should not occur with aprepitant on days 2 and 3 of any chemotherapy cycle."
                },
                {
                    "DetailID": "001c",
                    "PBSCode": "2518M",
                    "Streamline": "4215",
                    "PBSQty": "1",
                    "PBSRepeats": "5",
                    "Category": "GE",
                    "Restriction": "A",
                    "Type": "General",
                    "ScriptType": "Streamline Authority",
                    "Diagnosis": "Nausea and vomiting (moderately emetogenic cytotoxic chemotherapy)",
                    "Treatment": "",
                    "Criteria": "The condition must be associated with cytotoxic chemotherapy being used to treat breast cancer, AND The treatment must be in combination with a 5-hydroxytryptamine receptor (5HT3) antagonist and dexamethasone, AND Patient must be scheduled to be co-administered cyclophosphamide and an anthracycline. No more than 1 capsule of aprepitant 165 mg will be authorised per cycle of cytotoxic chemotherapy."
      },
                {
                    "DetailID": "001d",
                    "PBSCode": "2550F",
                    "Streamline": "4216",
                    "PBSQty": "1",
                    "PBSRepeats": "5",
                    "Category": "CT",
                    "Restriction": "A",
                    "Type": "General",
                    "Route": "Oral",
                    "ScriptType": "Streamline Authority",
                    "Diagnosis": "Nausea and vomiting (breast cancer)",
                    "Treatment": "",
                    "Criteria": "The condition must be associated with cytotoxic chemotherapy being used to treat breast cancer, AND The treatment must be in combination with a 5-hydroxytryptamine receptor (5HT3) antagonist and dexamethasone, AND Patient must be scheduled to be co-administered cyclophosphamide and an anthracycline. No more than 1 capsule of aprepitant 165 mg will be authorised per cycle of cytotoxic chemotherapy."
                },
                {
                    "DetailID": "001e",
                    "PBSCode": "2550F",
                    "Streamline": "4217",
                    "PBSQty": "1",
                    "PBSRepeats": "5",
                    "Category": "CT",
                    "Restriction": "A",
                    "Type": "General",
                    "ScriptType": "Streamline Authority",
                    "Diagnosis": "Nausea and vomiting (moderately emetogenic cytotoxic chemotherapy)",
                    "Treatment": "",
                    "Criteria": "The condition must be associated with moderately emetogenic cytotoxic chemotherapy being used to treat malignancy, AND The treatment must be in combination with a 5-hydroxytryptamine receptor (5HT3) antagonist and dexamethasone on day 1 of a chemotherapy cycle, AND Patient must have had a prior episode of chemotherapy induced nausea or vomiting, AND Patient must be scheduled to be administered a chemotherapy regimen that includes any 1 of the following intravenous chemotherapy agents: arsenic trioxide; azacitidine; carboplatin; cyclophosphamide at a dose of less than 1500 mg per square metre per day; cytarabine at a dose of greater than 1 g per square metre per day; dactinomycin; daunorubicin; doxorubicin; epirubicin; fotemustine; idarubicin; ifosfamide; irinotecan; melphalan; methotrexate at a dose of 250 mg to 1 g per square metre; oxaliplatin; raltitrexed. No more than 1 capsule of aprepitant 165 mg will be authorised per cycle of cytotoxic chemotherapy. Concomitant use of a 5HT3 antagonist should not occur with aprepitant on days 2 and 3 of any chemotherapy cycle."
                },
                {
                    "DetailID": "001f",
                    "PBSCode": "2550F",
                    "Streamline": "4223",
                    "PBSQty": "1",
                    "PBSRepeats": "5",
                    "Category": "CT",
                    "Restriction": "A",
                    "Type": "General",
                    "ScriptType": "Streamline Authority",
                    "Diagnosis": "Nausea and vomiting (with cytotoxic chemotherapy)",
                    "Treatment": "",
                    "Criteria": "The condition must be associated with cytotoxic chemotherapy being used to treat malignancy, AND The treatment must be in combination with a 5-hydroxytryptamine receptor (5HT3) antagonist and dexamethasone, AND Patient must be scheduled to be administered a chemotherapy regimen that includes any 1 of the following agents: altretamine; carmustine; cisplatin when a single dose constitutes a cycle of chemotherapy; cyclophosphamide at a dose of 1500 mg per square metre per day or greater; dacarbazine; procarbazine when a single dose constitutes a cycle of chemotherapy; streptozocin. No more than 1 capsule of aprepitant 165 mg will be authorised per cycle of cytotoxic chemotherapy."
                }
                    ]
      },
        {
            "ID": "2",
            "DrugID": "002",
            "Drug": "Arsenic",
            "Strength": "",
            "Route": "Injectable",
            "Website": "http://www.pbs.gov.au/pbs/search?term=Arsenic&search-type=medicines&analyse=false",
            "Details": [
                {
                    "DetailID": "002a",
                    "PBSCode": "7241D",
                    "Streamline": "4793",
                    "PBSQty": "18",
                    "PBSRepeats": "89",
                    "Category": "IN",
                    "Restriction": "A",
                    "Type": "Private",
                    "ScriptType": "Streamline Authority",
                    "Diagnosis": "Acute promyelocytic leukaemia",
                    "Treatment": "Induction and consolidation treatment",
                    "Criteria": "The condition must be characterised by the presence of the t(15:17) translocation or PML/RAR-alpha fusion gene transcript, AND The condition must be relapsed, AND Patient must be arsenic naive at induction."
        }
            ]


      },
        {
            "ID": "3",
            "DrugID": "003",
            "Drug": "Bevacizumab",
            "Strength": "",
            "Route": "Injectable",
            "Website": "http://www.pbs.gov.au/pbs/search?term=Bevacizumab&search-type=medicines&analyse=false",
            "Details": [
                {
                    "DetailID": "003a",
                    "PBSCode": "10114H",
                    "Streamline": "4584",
                    "PBSQty": "900",
                    "PBSRepeats": "11",
                    "Category": "IN",
                    "Restriction": "A",
                    "Type": "Private",
                    "ScriptType": "Streamline Authority",
                    "Diagnosis": "Stage IIIB, IIIC or Stage IV epithelial ovarian, fallopian tube or primary peritoneal cancer",
                    "Treatment": "Continuing treatment",
                    "Criteria": "Patient must have previously received PBS-subsidised treatment with bevacizumab for this condition, AND Patient must not have progressive disease, AND The treatment must not exceed a dose of 7.5 mg per kg every 3 weeks, AND The treatment must not exceed a lifetime total of 18 cycles of bevacizumab for epithelial ovarian, fallopian tube or primary peritoneal cancer."
                },
                {
                    "DetailID": "003b",
                    "PBSCode": "7243F",
                    "Streamline": "4587",
                    "PBSQty": "900",
                    "PBSRepeats": "11",
                    "Category": "IN",
                    "Restriction": "A",
                    "Type": "Private",
                    "ScriptType": "Streamline Authority",
                    "Diagnosis": "Metastatic colorectal cancer",
                    "Treatment": "Continuing treatment",
                    "Criteria": "Patient must have previously received PBS-subsidised treatment with bevacizumab for this condition, AND Patient must not have progressive disease, AND The treatment must be in combination with first-line chemotherapy, AND The treatment must not exceed a dose of 5 mg per kg every 2 weeks; OR The treatment must not exceed a dose of 7.5 mg per kg every 3 weeks. The patient's body weight must be documented in the patient's medical records at the time the treatment cycle is initiated."
                },
                {
                    "DetailID": "003c",
                    "PBSCode": "7243F",
                    "Streamline": "4594",
                    "PBSQty": "900",
                    "PBSRepeats": "11",
                    "Category": "IN",
                    "Restriction": "A",
                    "Type": "Private",
                    "ScriptType": "Streamline Authority",
                    "Diagnosis": "Metastatic colorectal cancer",
                    "Treatment": "Initial treatment",
                    "Criteria": "The condition must be previously untreated, AND Patient must have a WHO performance status of 0 or 1, AND The treatment must be in combination with first-line chemotherapy, AND The treatment must not exceed a dose of 5 mg per kg every 2 weeks; OR The treatment must not exceed a dose of 7.5 mg per kg every 3 weeks. The patient's WHO performance status and body weight must be documented in the patient's medical records at the time the treatment cycle is initiated."
      },
                {
                    "DetailID": "003d",
                    "PBSCode": "10120P",
                    "Streamline": "4814",
                    "PBSQty": "900",
                    "PBSRepeats": "5",
                    "Category": "IN",
                    "Restriction": "A",
                    "Type": "Private",
                    "ScriptType": "Streamline Authority",
                    "Diagnosis": "Stage IIIB, IIIC or Stage IV epithelial ovarian, fallopian tube or primary peritoneal cancer ",
                    "Treatment": "Initial treatment",
                    "Criteria": "The condition must be suboptimally debulked (maximum diameter of any gross residual disease greater than 1 cm) only if the patient presents with Stage IIIB or Stage IIIC disease, AND Patient must have a WHO performance status of 2 or less, AND The condition must be previously untreated, AND The treatment must be commenced in combination with platinum-based chemotherapy, AND The treatment must not exceed a dose of 7.5 mg per kg every 3 weeks, AND The treatment must not exceed a lifetime total of 18 cycles of bevacizumab for epithelial ovarian, fallopian tube or primary peritoneal cancer. The patient's WHO performance status and body weight must be documented in the patient's medical records at the time the treatment cycle is initiated."
      },
                {
                    "DetailID": "003e",
                    "PBSCode": "7243F",
                    "Streamline": "4939",
                    "PBSQty": "900",
                    "PBSRepeats": "11",
                    "Category": "IN",
                    "Restriction": "A",
                    "Type": "Private",
                    "ScriptType": "Streamline Authority",
                    "Diagnosis": "Metastatic colorectal cancer",
                    "Treatment": "Initial treatment",
                    "Criteria": "Patient must have RAS wild-type metastatic colorectal cancer, AND Patient must be previously treated with PBS-subsidised first-line anti-EGFR antibodies, AND Patient must not have previously received PBS-subsidised treatment with this drug for this condition, AND Patient must have a WHO performance status of 0 or 1, AND The treatment must be in combination with second-line chemotherapy, AND The treatment must not exceed a dose of 5 mg per kg every 2 weeks; OR The treatment must not exceed a dose of 7.5 mg per kg every 3 weeks."
      },
                {
                    "DetailID": "003f",
                    "PBSCode": "7243F",
                    "Streamline": "4968",
                    "PBSQty": "900",
                    "PBSRepeats": "11",
                    "Category": "IN",
                    "Restriction": "A",
                    "Type": "Private",
                    "ScriptType": "Streamline Authority",
                    "Diagnosis": "Metastatic colorectal cancer",
                    "Treatment": "Continuing treatment",
                    "Criteria": "Patient must have previously received PBS-subsidised treatment with this drug for this condition, AND Patient must not have progressive disease, AND The treatment must be in combination with second-line chemotherapy, AND The treatment must not exceed a dose of 5 mg per kg every 2 weeks; OR The treatment must not exceed a dose of 7.5 mg per kg every 3 weeks."
      }
            ]
      },

        {
            "ID": "21",
            "DrugID": "004",
            "Drug": "Bicalutamide",
            "Strength": "50mg",
            "PBSCode": "8094B",
            "Streamline": "3674",
            "PBSQty": "28",
            "PBSRepeats": "5",
            "Category": "GE",
            "Restriction": "A",
            "Type": "General",
            "Route": "Injectable",
            "ScriptType": "Streamline Authority",
            "Diagnosis": "Metastatic prostatic carcinoma",
            "Treatment": "",
            "Criteria": "Metastatic (equivalent to stage D) prostatic carcinoma in combination with GnRH (LH-RH) analogue therapy",
            "Website": "http://www.pbs.gov.au/pbs/search?term=Bicalutamide&search-type=medicines&analyse=false"
      },
        {
            "ID": "23",
            "DrugID": "005",
            "Drug": "Cabazitaxel",
            "Strength": "",
            "PBSCode": "7236W",
            "Streamline": "4662",
            "PBSQty": "55",
            "PBSRepeats": "5",
            "Category": "IN",
            "Restriction": "A",
            "Type": "Private",
            "Route": "Injectable",
            "ScriptType": "Streamline Authority",
            "Diagnosis": "Castration resistant metastatic carcinoma of the prostate ",
            "Treatment": "Initial treatment",
            "Criteria": "The treatment must be in combination with prednisone or prednisolone, AND The treatment must not be used in combination with abiraterone, AND Patient must have failed treatment with docetaxel due to resistance or intolerance, AND Patient must have a WHO performance status of 2 or less, AND Patient must not receive PBS-subsidised cabazitaxel if progressive disease develops while on cabazitaxel.",
            "Website": "http://www.pbs.gov.au/pbs/search?term=Cabazitaxel&search-type=medicines&analyse=false"
      },
        {
            "ID": "25",
            "DrugID": "006",
            "Drug": "Cetuximab",
            "Strength": "",
            "PBSCode": "7223E",
            "Streamline": "4785",
            "PBSQty": "880",
            "PBSRepeats": "0",
            "Category": "IN",
            "Restriction": "A",
            "Type": "Private",
            "Route": "Injectable",
            "ScriptType": "Streamline Authority",
            "Diagnosis": "Stage III, IVa or IVb squamous cell cancer of the larynx, oropharynx or hypopharynx ",
            "Treatment": "Initial treatment",
            "Criteria": "The treatment must be in combination with radiotherapy, AND Patient must be unable to tolerate cisplatin.",
            "Website": "http://www.pbs.gov.au/pbs/search?term=Cetuximab&search-type=medicines&analyse=false"
      },
        {
            "ID": "27",
            "DrugID": "006",
            "Drug": "Cetuximab",
            "Strength": "",
            "PBSCode": "7240C",
            "Streamline": "4788",
            "PBSQty": "550",
            "PBSRepeats": "5",
            "Category": "IN",
            "Restriction": "A",
            "Type": "Private",
            "Route": "Injectable",
            "ScriptType": "Streamline Authority",
            "Diagnosis": "Stage III, IVa or IVb squamous cell cancer of the larynx, oropharynx or hypopharynx ",
            "Treatment": "Continuing treatment",
            "Criteria": "The treatment must be in combination with radiotherapy, AND Patient must be unable to tolerate cisplatin; OR Patient must have a contraindication to cisplatin according to the TGA-approved Product Information.",
            "Website": "http://www.pbs.gov.au/pbs/search?term=Cetuximab&search-type=medicines&analyse=false"
      },
        {
            "ID": "29",
            "DrugID": "006",
            "Drug": "Cetuximab",
            "Strength": "",
            "PBSCode": "7223E",
            "Streamline": "4794",
            "PBSQty": "880",
            "PBSRepeats": "0",
            "Category": "IN",
            "Restriction": "A",
            "Type": "Private",
            "Route": "Injectable",
            "ScriptType": "Streamline Authority",
            "Diagnosis": "Stage III, IVa or IVb squamous cell cancer of the larynx, oropharynx or hypopharynx ",
            "Treatment": "Initial treatment",
            "Criteria": "The treatment must be for the week prior to radiotherapy, AND Patient must have a contraindication to cisplatin according to the TGA-approved Product Information.",
            "Website": "http://www.pbs.gov.au/pbs/search?term=Cetuximab&search-type=medicines&analyse=false"
      },
        {
            "ID": "31",
            "DrugID": "006",
            "Drug": "Cetuximab",
            "Strength": "",
            "PBSCode": "7242E",
            "Streamline": "4908",
            "PBSQty": "880",
            "PBSRepeats": "0",
            "Category": "IN",
            "Restriction": "A",
            "Type": "Private",
            "Route": "Injectable",
            "ScriptType": "Streamline Authority",
            "Diagnosis": "Metastatic colorectal cancer ",
            "Treatment": "Initial treatment",
            "Criteria": "Patient must have RAS wild-type metastatic colorectal cancer, AND Patient must have a WHO performance status of 0 or 1, AND The condition must be previously untreated, AND The treatment must be in combination with first-line chemotherapy, AND The treatment must be the sole PBS-subsidised anti-EGFR antibody therapy for this condition.",
            "Website": "http://www.pbs.gov.au/pbs/search?term=Cetuximab&search-type=medicines&analyse=false"
      },
        {
            "ID": "33",
            "DrugID": "006",
            "Drug": "Cetuximab",
            "Strength": "",
            "PBSCode": "10265G",
            "Streamline": "4912",
            "PBSQty": "550",
            "PBSRepeats": "18",
            "Category": "IN",
            "Restriction": "A",
            "Type": "Private",
            "Route": "Injectable",
            "ScriptType": "Streamline Authority",
            "Diagnosis": "Metastatic colorectal cancer ",
            "Treatment": "Continuing treatment",
            "Criteria": "Patient must have received an initial authority prescription for this drug for first-line treatment of RAS wild-type metastatic colorectal cancer, AND Patient must not have progressive disease, AND The treatment must be in combination with first-line chemotherapy, AND The treatment must be the sole PBS-subsidised anti-EGFR antibody therapy for this condition.",
            "Website": "http://www.pbs.gov.au/pbs/search?term=Cetuximab&search-type=medicines&analyse=false"
      },
        {
            "ID": "35",
            "DrugID": "006",
            "Drug": "Cetuximab",
            "Strength": "",
            "PBSCode": "7273T",
            "Streamline": "4945",
            "PBSQty": "550",
            "PBSRepeats": "11",
            "Category": "IN",
            "Restriction": "A",
            "Type": "Private",
            "Route": "Injectable",
            "ScriptType": "Streamline Authority",
            "Diagnosis": "Metastatic colorectal cancer ",
            "Treatment": "Continuing treatment",
            "Criteria": "Patient must have received an initial authority prescription for this drug for treatment of RAS wild-type metastatic colorectal cancer after failure of first-line chemotherapy, AND Patient must not have progressive disease, AND The treatment must be as monotherapy; OR The treatment must be in combination with chemotherapy, AND The treatment must be the sole PBS-subsidised anti-EGFR antibody therapy for this condition. Patients who have progressive disease on panitumumab are not eligible to receive PBS-subsidised cetuximab. Patients who have developed intolerance to panitumumab of a severity necessitating permanent treatment withdrawal are eligible to receive PBS-subsidised cetuximab.",
            "Website": "http://www.pbs.gov.au/pbs/search?term=Cetuximab&search-type=medicines&analyse=false"
      },
        {
            "ID": "37",
            "DrugID": "006",
            "Drug": "Cetuximab",
            "Strength": "",
            "PBSCode": "7242E",
            "Streamline": "4965",
            "PBSQty": "880",
            "PBSRepeats": "0",
            "Category": "IN",
            "Restriction": "A",
            "Type": "Private",
            "Route": "Injectable",
            "ScriptType": "Streamline Authority",
            "Diagnosis": "Metastatic colorectal cancer ",
            "Treatment": "Initial treatment",
            "Criteria": "Patient must have RAS wild-type metastatic colorectal cancer, AND Patient must have a WHO performance status of 2 or less, AND The condition must have failed to respond to first-line chemotherapy, AND The treatment must be as monotherapy; OR The treatment must be in combination with chemotherapy, AND The treatment must be the sole PBS-subsidised anti-EGFR antibody therapy for this condition. Patients who have progressive disease on panitumumab are not eligible to receive PBS-subsidised cetuximab. Patients who have developed intolerance to panitumumab of a severity necessitating permanent treatment withdrawal are eligible to receive PBS-subsidised cetuximab.",
            "Website": "http://www.pbs.gov.au/pbs/search?term=Cetuximab&search-type=medicines&analyse=false"
      },
        {
            "ID": "39",
            "DrugID": "007",
            "Drug": "Cladribine",
            "Strength": "",
            "PBSCode": "7225G",
            "Streamline": "3180",
            "PBSQty": "17",
            "PBSRepeats": "6",
            "Category": "IN",
            "Restriction": "A",
            "Type": "Private",
            "Route": "Injectable",
            "ScriptType": "Streamline Authority",
            "Diagnosis": "Hairy cell leukaemia",
            "Treatment": "",
            "Criteria": "Hairy cell leukaemia",
            "Website": "http://www.pbs.gov.au/pbs/search?term=Cladribine&search-type=medicines&analyse=false"
      },
        {
            "ID": "40",
            "DrugID": "008",
            "Drug": "Denosumab",
            "Strength": "120mg",
            "PBSCode": "5110Y",
            "Streamline": "4150",
            "PBSQty": "1",
            "PBSRepeats": "5",
            "Category": "GE",
            "Restriction": "A",
            "Type": "General",
            "Route": "Injectable",
            "ScriptType": "Streamline Authority",
            "Diagnosis": "Bone metastases (prostate cancer).",
            "Treatment": "",
            "Criteria": "Bone metastases Clinical criteria: The condition must be due to castration-resistant prostate cancer.",
            "Website": "http://www.pbs.gov.au/pbs/search?term=Denosumab&search-type=medicines&analyse=false"
      },
        {
            "ID": "41",
            "DrugID": "008",
            "Drug": "Denosumab",
            "Strength": "120mg",
            "PBSCode": "5110Y",
            "Streamline": "4158",
            "PBSQty": "1",
            "PBSRepeats": "5",
            "Category": "GE",
            "Restriction": "A",
            "Type": "General",
            "Route": "Injectable",
            "ScriptType": "Streamline Authority",
            "Diagnosis": "Bone metastases (breast cancer)",
            "Treatment": "",
            "Criteria": "Bone metastases Clinical criteria: The condition must be due to breast cancer.",
            "Website": "http://www.pbs.gov.au/pbs/search?term=Denosumab&search-type=medicines&analyse=false"
      },
        {
            "ID": "42",
            "DrugID": "008",
            "Drug": "Denosumab",
            "Strength": "120mg",
            "PBSCode": "10061M",
            "Streamline": "4504",
            "PBSQty": "1",
            "PBSRepeats": "5",
            "Category": "GE",
            "Restriction": "A",
            "Type": "General",
            "Route": "Injectable",
            "ScriptType": "Streamline Authority",
            "Diagnosis": "Giant cell tumour of bone ",
            "Treatment": "",
            "Criteria": "Giant cell tumour of bone Clinical criteria: Patient must be one in whom surgical resection is not feasible; OR Patient must be one in whom surgical resection is possible but surgery would result in significant morbidity. Population criteria: Patient must be an adult; OR Patient must be a skeletally mature adolescent.",
            "Website": "http://www.pbs.gov.au/pbs/search?term=Denosumab&search-type=medicines&analyse=false"
      },
        {
            "ID": "47",
            "DrugID": "010",
            "Drug": "Doxorubicin Liposomal",
            "Strength": "",
            "PBSCode": "7230M",
            "Streamline": "4786",
            "PBSQty": "100",
            "PBSRepeats": "5",
            "Category": "IN",
            "Restriction": "A",
            "Type": "Private",
            "Route": "Injectable",
            "ScriptType": "Streamline Authority",
            "Diagnosis": "Advanced epithelial ovarian cancer",
            "Treatment": "",
            "Criteria": "Patient must have failed a first-line platinum-based chemotherapy regimen.",
            "Website": "http://www.pbs.gov.au/pbs/search?term=Doxorubicin Liposomal&search-type=medicines&analyse=false"
      },
        {
            "ID": "49",
            "DrugID": "010",
            "Drug": "Doxorubicin Liposomal",
            "Strength": "",
            "PBSCode": "7230M",
            "Streamline": "4787",
            "PBSQty": "100",
            "PBSRepeats": "5",
            "Category": "IN",
            "Restriction": "A",
            "Type": "Private",
            "Route": "Injectable",
            "ScriptType": "Streamline Authority",
            "Diagnosis": "Metastatic breast cancer ",
            "Treatment": "",
            "Criteria": "The treatment must be as monotherapy, AND Patient must have a contraindication to therapy with capecitabine and/or a taxane.",
            "Website": "http://www.pbs.gov.au/pbs/search?term=Doxorubicin Liposomal&search-type=medicines&analyse=false"
      },
        {
            "ID": "51",
            "DrugID": "010",
            "Drug": "Doxorubicin Liposomal",
            "Strength": "",
            "PBSCode": "7230M",
            "Streamline": "4791",
            "PBSQty": "100",
            "PBSRepeats": "5",
            "Category": "IN",
            "Restriction": "A",
            "Type": "Private",
            "Route": "Injectable",
            "ScriptType": "Streamline Authority",
            "Diagnosis": "Metastatic breast cancer ",
            "Treatment": "",
            "Criteria": "The treatment must be as monotherapy, AND Patient must have failed prior therapy which included capecitabine and a taxane.",
            "Website": "http://www.pbs.gov.au/pbs/search?term=Doxorubicin Liposomal&search-type=medicines&analyse=false"
      },
        {
            "ID": "270",
            "DrugID": "012",
            "Drug": "Fotemustine",
            "Strength": "",
            "PBSCode": "7245H",
            "Streamline": "3181",
            "PBSQty": "220",
            "PBSRepeats": "8",
            "Category": "IN",
            "Restriction": "A",
            "Type": "Private",
            "Route": "Injectable",
            "ScriptType": "Streamline Authority",
            "Diagnosis": "Metastatic malignant melanoma",
            "Treatment": "",
            "Criteria": "Metastatic malignant melanoma",
            "Website": "http://www.pbs.gov.au/pbs/search?term=Fotemustine&search-type=medicines&analyse=false"
      },
        {
            "ID": "271",
            "DrugID": "013",
            "Drug": "Granisetron",
            "Strength": "3mg",
            "PBSCode": "8730L",
            "Streamline": "4092",
            "PBSQty": "1",
            "PBSRepeats": "0",
            "Category": "GE",
            "Restriction": "A",
            "Type": "General",
            "Route": "Injectable",
            "ScriptType": "Streamline Authority",
            "Diagnosis": "Nausea and vomiting",
            "Treatment": "",
            "Criteria": "The condition must be associated with radiotherapy being used to treat malignancy.",
            "Website": "http://www.pbs.gov.au/pbs/search?term=Granisetron&search-type=medicines&analyse=false"
      },
        {
            "ID": "272",
            "DrugID": "013",
            "Drug": "Granisetron",
            "Strength": "2mg",
            "PBSCode": "8873B",
            "Streamline": "4102",
            "PBSQty": "5",
            "PBSRepeats": "1",
            "Category": "GE",
            "Restriction": "A",
            "Type": "General",
            "Route": "Oral",
            "ScriptType": "Streamline Authority",
            "Diagnosis": "Nausea and vomiting",
            "Treatment": "",
            "Criteria": "The condition must be associated with radiotherapy being used to treat malignancy.",
            "Website": "http://www.pbs.gov.au/pbs/search?term=Granisetron&search-type=medicines&analyse=false"
      },
        {
            "ID": "275",
            "DrugID": "015",
            "Drug": "Ipilimumab",
            "Strength": "",
            "PBSCode": "2643D",
            "Streamline": "4251",
            "PBSQty": "360",
            "PBSRepeats": "2",
            "Category": "IN",
            "Restriction": "A",
            "Type": "Private",
            "Route": "Injectable",
            "ScriptType": "Streamline Authority",
            "Diagnosis": "Unresectable Stage III or Stage IV malignant melanoma",
            "Treatment": "Completion of induction treatment",
            "Criteria": "The treatment must be as monotherapy, AND The treatment must be for completion of induction treatment in a patient who commenced induction treatment with ipilimumab prior to 1 August 2013, AND The treatment must not exceed a total of 4 doses (combined PBS-subsidised and non-PBS-subsidised) at a maximum dose of 3 mg per kg every 3 weeks. The patient's body weight must be documented in the patient's medical records at the time treatment is initiated. For patients who commenced induction treatment with ipilimumab prior to 1 August 2013 prescribers should request the appropriate number of repeats to provide a total of 4 doses of ipilimumab (combined PBS-subsidised and non-PBS subsidised).",
            "Website": "http://www.pbs.gov.au/pbs/search?term=Ipilimumab&search-type=medicines&analyse=false"
      },
        {
            "ID": "277",
            "DrugID": "015",
            "Drug": "Ipilimumab",
            "Strength": "",
            "PBSCode": "2643D",
            "Streamline": "4252",
            "PBSQty": "360",
            "PBSRepeats": "2",
            "Category": "IN",
            "Restriction": "A",
            "Type": "Private",
            "Route": "Injectable",
            "ScriptType": "Streamline Authority",
            "Diagnosis": "Unresectable Stage III or Stage IV malignant melanoma",
            "Treatment": "Completion of re-induction treatment",
            "Criteria": "The treatment must be as monotherapy, AND Patient must have progressive disease after achieving an initial objective response to the most recent course of ipilimumab treatment (induction or re-induction) received prior to 1 August 2013, AND The treatment must be for completion of re-induction treatment in a patient who commenced re-induction treatment with ipilimumab prior to 1 August 2013, AND The treatment must not exceed a total of 4 doses (combined PBS-subsidised and non-PBS-subsidised) at a maximum dose of 3 mg per kg every 3 weeks. An initial objective response to treatment is defined as either:(i) sustained stable disease of greater than or equal to 3 months duration measured from at least 2 weeks after the date of completion of the most recent course of ipilimumab; or(ii) a partial or complete response. The patient's body weight must be documented in the patient's medical records at the time treatment with ipilimumab is initiated. For patients who commenced re-induction treatment with ipilimumab prior to 1 August 2013 prescribers should request the appropriate number of repeats to provide a maximum of 4 doses of ipilimumab (combined PBS-subsidised and non-PBS-subsidised).",
            "Website": "http://www.pbs.gov.au/pbs/search?term=Ipilimumab&search-type=medicines&analyse=false"
      },
        {
            "ID": "279",
            "DrugID": "015",
            "Drug": "Ipilimumab",
            "Strength": "",
            "PBSCode": "2638W",
            "Streamline": "4254",
            "PBSQty": "360",
            "PBSRepeats": "3",
            "Category": "IN",
            "Restriction": "A",
            "Type": "Private",
            "Route": "Injectable",
            "ScriptType": "Streamline Authority",
            "Diagnosis": "Unresectable Stage III or Stage IV malignant melanoma",
            "Treatment": "Induction treatment",
            "Criteria": "The treatment must be as monotherapy, AND Patient must not have received prior treatment with ipilimumab, AND The treatment must not exceed a total of 4 doses at a maximum dose of 3 mg per kg every 3 weeks. The patient's body weight must be documented in the patient's medical records at the time treatment is initiated.",
            "Website": "http://www.pbs.gov.au/pbs/search?term=Ipilimumab&search-type=medicines&analyse=false"
      },
        {
            "ID": "281",
            "DrugID": "015",
            "Drug": "Ipilimumab",
            "Strength": "",
            "PBSCode": "2638W",
            "Streamline": "4261",
            "PBSQty": "360",
            "PBSRepeats": "3",
            "Category": "IN",
            "Restriction": "A",
            "Type": "Private",
            "Route": "Injectable",
            "ScriptType": "Streamline Authority",
            "Diagnosis": "Unresectable Stage III or Stage IV malignant melanoma",
            "Treatment": "Re-induction treatment",
            "Criteria": "The treatment must be as monotherapy, AND Patient must have progressive disease after achieving an initial objective response to the most recent course of ipilimumab treatment (induction or re-induction), AND The treatment must not exceed a total of 4 doses at a maximum dose of 3 mg per kg every 3 weeks. An initial objective response to treatment is defined as either:(i) sustained stable disease of greater than or equal to 3 months duration measured from at least 2 weeks after the date of completion of the most recent course of ipilimumab; or(ii) a partial or complete response. The patient's body weight must be documented in the patient's medical records at the time treatment with ipilimumab is initiated.",
            "Website": "http://www.pbs.gov.au/pbs/search?term=Ipilimumab&search-type=medicines&analyse=false"
      },
        {
            "ID": "283",
            "DrugID": "016",
            "Drug": "Iron Polymaltose",
            "Strength": "",
            "PBSCode": "2805P",
            "Streamline": "4302",
            "PBSQty": "5",
            "PBSRepeats": "5",
            "Category": "GE",
            "Restriction": "A",
            "Type": "General",
            "Route": "Injectable",
            "ScriptType": "Streamline Authority",
            "Diagnosis": "Iron deficiency anaemia",
            "Treatment": "Patient must be undergoing chronic haemodialysis.",
            "Criteria": "Iron deficiency anaemia Treatment criteria: Patient must be undergoing chronic haemodialysis.",
            "Website": "http://www.pbs.gov.au/pbs/search?term=Iron Polymaltose&search-type=medicines&analyse=false"
      },
        {
            "ID": "284",
            "DrugID": "017",
            "Drug": "Iron Sucrose",
            "Strength": "",
            "PBSCode": "8807M",
            "Streamline": "4302",
            "PBSQty": "5",
            "PBSRepeats": "5",
            "Category": "GE",
            "Restriction": "A",
            "Type": "General",
            "Route": "Injectable",
            "ScriptType": "Streamline Authority",
            "Diagnosis": "Iron deficiency anaemia",
            "Treatment": "Patient must be undergoing chronic haemodialysis.",
            "Criteria": "Iron deficiency anaemia Treatment criteria: Patient must be undergoing chronic haemodialysis.",
            "Website": "http://www.pbs.gov.au/pbs/search?term=Iron Sucrose&search-type=medicines&analyse=false"
      },
        {
            "ID": "307",
            "DrugID": "019",
            "Drug": "Nilutamide",
            "Strength": "150mg",
            "PBSCode": "8131Y",
            "Streamline": "3300",
            "PBSQty": "30",
            "PBSRepeats": "5",
            "Category": "GE",
            "Restriction": "A",
            "Type": "General",
            "Route": "Oral",
            "ScriptType": "Streamline Authority",
            "Diagnosis": "Prostatic carcinoma",
            "Treatment": "",
            "Criteria": "Locally advanced (equivalent to stage C) or metastatic (equivalent to stage D) prostatic carcinoma, in conjunction with surgical orchidectomy",
            "Website": "http://www.pbs.gov.au/pbs/search?term=Nilutamide&search-type=medicines&analyse=false"
      },
        {
            "ID": "308",
            "DrugID": "019",
            "Drug": "Nilutamide",
            "Strength": "150mg",
            "PBSCode": "8131Y",
            "Streamline": "3675",
            "PBSQty": "30",
            "PBSRepeats": "5",
            "Category": "GE",
            "Restriction": "A",
            "Type": "General",
            "Route": "Oral",
            "ScriptType": "Streamline Authority",
            "Diagnosis": "Prostatic carcinoma",
            "Treatment": "",
            "Criteria": "Locally advanced (equivalent to stage C) or metastatic (equivalent to stage D) prostatic carcinoma, in combination with GnRH (LH-RH) analogue therapy",
            "Website": "http://www.pbs.gov.au/pbs/search?term=Nilutamide&search-type=medicines&analyse=false"
      },
        {
            "ID": "309",
            "DrugID": "020",
            "Drug": "Ofatumumab",
            "Strength": "",
            "PBSCode": "10239X",
            "Streamline": "4828",
            "PBSQty": "1000",
            "PBSRepeats": "5",
            "Category": "IN",
            "Restriction": "A",
            "Type": "Private",
            "Route": "Injectable",
            "ScriptType": "Streamline Authority",
            "Diagnosis": "Chronic lymphocytic leukaemia (CLL)",
            "Treatment": "Initial treatment",
            "Criteria": "The condition must be CD20 positive chronic lymphocytic leukaemia (CLL), AND The condition must be previously untreated, AND The treatment must be in combination with chlorambucil, AND Patient must be inappropriate for fludarabine based therapy.",
            "Website": "http://www.pbs.gov.au/pbs/search?term=Ofatumumab&search-type=medicines&analyse=false"
      },
        {
            "ID": "310",
            "DrugID": "020",
            "Drug": "Ofatumumab",
            "Strength": "",
            "PBSCode": "10240Y",
            "Streamline": "4828",
            "PBSQty": "300",
            "PBSRepeats": "0",
            "Category": "IN",
            "Restriction": "A",
            "Type": "Private",
            "Route": "Injectable",
            "ScriptType": "Streamline Authority",
            "Diagnosis": "Chronic lymphocytic leukaemia (CLL)",
            "Treatment": "Initial treatment",
            "Criteria": "The condition must be CD20 positive chronic lymphocytic leukaemia (CLL), AND The condition must be previously untreated, AND The treatment must be in combination with chlorambucil, AND Patient must be inappropriate for fludarabine based therapy.",
            "Website": "http://www.pbs.gov.au/pbs/search?term=Ofatumumab&search-type=medicines&analyse=false"
      },
        {
            "ID": "314",
            "DrugID": "020",
            "Drug": "Ofatumumab",
            "Strength": "",
            "PBSCode": "10237T",
            "Streamline": "4858",
            "PBSQty": "1000",
            "PBSRepeats": "5",
            "Category": "IN",
            "Restriction": "A",
            "Type": "Private",
            "Route": "Injectable",
            "ScriptType": "Streamline Authority",
            "Diagnosis": "Chronic lymphocytic leukaemia (CLL)",
            "Treatment": "Continuing treatment",
            "Criteria": "The condition must be CD20 positive chronic lymphocytic leukaemia (CLL), AND Patient must have previously been issued with an authority prescription for this drug, AND Patient must not have progressive disease, AND Patient must be inappropriate for fludarabine based therapy, AND The treatment must be in combination with chlorambucil.",
            "Website": "http://www.pbs.gov.au/pbs/search?term=Ofatumumab&search-type=medicines&analyse=false"
      },
        {
            "ID": "315",
            "DrugID": "021",
            "Drug": "Ondansetron",
            "Strength": "4mg",
            "PBSCode": "1594X",
            "Streamline": "3611",
            "PBSQty": "10",
            "PBSRepeats": "1",
            "Category": "GE",
            "Restriction": "A",
            "Type": "General",
            "Route": "Injectable",
            "ScriptType": "Streamline Authority",
            "Diagnosis": "Nausea and vomiting",
            "Treatment": "",
            "Criteria": "Management of nausea and vomiting associated with radiotherapy being used to treat malignancy",
            "Website": "http://www.pbs.gov.au/pbs/search?term=Ondansetron&search-type=medicines&analyse=false"
      },
        {
            "ID": "316",
            "DrugID": "021",
            "Drug": "Ondansetron",
            "Strength": "8mg",
            "PBSCode": "1595Y",
            "Streamline": "3611",
            "PBSQty": "10",
            "PBSRepeats": "1",
            "Category": "GE",
            "Restriction": "A",
            "Type": "General",
            "Route": "Injectable",
            "ScriptType": "Streamline Authority",
            "Diagnosis": "Nausea and vomiting",
            "Treatment": "",
            "Criteria": "Management of nausea and vomiting associated with radiotherapy being used to treat malignancy",
            "Website": "http://www.pbs.gov.au/pbs/search?term=Ondansetron&search-type=medicines&analyse=false"
      },
        {
            "ID": "317",
            "DrugID": "021",
            "Drug": "Ondansetron",
            "Strength": "4mg/2",
            "PBSCode": "1596B",
            "Streamline": "3611",
            "PBSQty": "1",
            "PBSRepeats": "0",
            "Category": "GE",
            "Restriction": "A",
            "Type": "General",
            "Route": "Injectable",
            "ScriptType": "Streamline Authority",
            "Diagnosis": "Nausea and vomiting",
            "Treatment": "",
            "Criteria": "Management of nausea and vomiting associated with radiotherapy being used to treat malignancy",
            "Website": "http://www.pbs.gov.au/pbs/search?term=Ondansetron&search-type=medicines&analyse=false"
      },
        {
            "ID": "318",
            "DrugID": "021",
            "Drug": "Ondansetron",
            "Strength": "8mg/4",
            "PBSCode": "1597C",
            "Streamline": "3611",
            "PBSQty": "1",
            "PBSRepeats": "0",
            "Category": "GE",
            "Restriction": "A",
            "Type": "General",
            "Route": "Injectable",
            "ScriptType": "Streamline Authority",
            "Diagnosis": "Nausea and vomiting",
            "Treatment": "",
            "Criteria": "Management of nausea and vomiting associated with radiotherapy being used to treat malignancy",
            "Website": "http://www.pbs.gov.au/pbs/search?term=Ondansetron&search-type=medicines&analyse=false"
      },
        {
            "ID": "319",
            "DrugID": "021",
            "Drug": "Ondansetron",
            "Strength": "Tablet(orally",
            "PBSCode": "5472B",
            "Streamline": "3611",
            "PBSQty": "10",
            "PBSRepeats": "1",
            "Category": "GE",
            "Restriction": "A",
            "Type": "General",
            "Route": "Injectable",
            "ScriptType": "Streamline Authority",
            "Diagnosis": "Nausea and vomiting",
            "Treatment": "",
            "Criteria": "Management of nausea and vomiting associated with radiotherapy being used to treat malignancy",
            "Website": "http://www.pbs.gov.au/pbs/search?term=Ondansetron&search-type=medicines&analyse=false"
      },
        {
            "ID": "320",
            "DrugID": "021",
            "Drug": "Ondansetron",
            "Strength": "Tablet(orally",
            "PBSCode": "5473C",
            "Streamline": "3611",
            "PBSQty": "10",
            "PBSRepeats": "1",
            "Category": "GE",
            "Restriction": "A",
            "Type": "General",
            "Route": "Injectable",
            "ScriptType": "Streamline Authority",
            "Diagnosis": "Nausea and vomiting",
            "Treatment": "",
            "Criteria": "Management of nausea and vomiting associated with radiotherapy being used to treat malignancy",
            "Website": "http://www.pbs.gov.au/pbs/search?term=Ondansetron&search-type=medicines&analyse=false"
      },
        {
            "ID": "321",
            "DrugID": "021",
            "Drug": "Ondansetron",
            "Strength": "4mg/5",
            "PBSCode": "8233H",
            "Streamline": "3611",
            "PBSQty": "1",
            "PBSRepeats": "1",
            "Category": "GE",
            "Restriction": "A",
            "Type": "General",
            "Route": "Injectable",
            "ScriptType": "Streamline Authority",
            "Diagnosis": "Nausea and vomiting",
            "Treatment": "",
            "Criteria": "Management of nausea and vomiting associated with radiotherapy being used to treat malignancy",
            "Website": "http://www.pbs.gov.au/pbs/search?term=Ondansetron&search-type=medicines&analyse=false"
      },
        {
            "ID": "322",
            "DrugID": "021",
            "Drug": "Ondansetron",
            "Strength": "4mg",
            "PBSCode": "8412R",
            "Streamline": "3611",
            "PBSQty": "10",
            "PBSRepeats": "1",
            "Category": "GE",
            "Restriction": "A",
            "Type": "General",
            "Route": "Injectable",
            "ScriptType": "Streamline Authority",
            "Diagnosis": "Nausea and vomiting",
            "Treatment": "",
            "Criteria": "Management of nausea and vomiting associated with radiotherapy being used to treat malignancy",
            "Website": "http://www.pbs.gov.au/pbs/search?term=Ondansetron&search-type=medicines&analyse=false"
      },
        {
            "ID": "323",
            "DrugID": "021",
            "Drug": "Ondansetron",
            "Strength": "8mg",
            "PBSCode": "8413T",
            "Streamline": "3611",
            "PBSQty": "10",
            "PBSRepeats": "1",
            "Category": "GE",
            "Restriction": "A",
            "Type": "General",
            "Route": "Injectable",
            "ScriptType": "Streamline Authority",
            "Diagnosis": "Nausea and vomiting",
            "Treatment": "",
            "Criteria": "Management of nausea and vomiting associated with radiotherapy being used to treat malignancy",
            "Website": "http://www.pbs.gov.au/pbs/search?term=Ondansetron&search-type=medicines&analyse=false"
      },
        {
            "ID": "324",
            "DrugID": "022",
            "Drug": "Paclitaxel NAB",
            "Strength": "",
            "PBSCode": "7270P",
            "Streamline": "3955",
            "PBSQty": "580",
            "PBSRepeats": "5",
            "Category": "IN",
            "Restriction": "A",
            "Type": "Private",
            "Route": "Injectable",
            "ScriptType": "Streamline Authority",
            "Diagnosis": "Metastatic breast cancer",
            "Treatment": "",
            "Criteria": "Metastatic breast cancer",
            "Website": "http://www.pbs.gov.au/pbs/search?term=Paclitaxel NAB&search-type=medicines&analyse=false"
      },
        {
            "ID": "326",
            "DrugID": "022",
            "Drug": "Paclitaxel NAB",
            "Strength": "",
            "PBSCode": "7270P",
            "Streamline": "3956",
            "PBSQty": "580",
            "PBSRepeats": "5",
            "Category": "IN",
            "Restriction": "A",
            "Type": "Private",
            "Route": "Injectable",
            "ScriptType": "Streamline Authority",
            "Diagnosis": "HER2 positive breast cancer ",
            "Treatment": "",
            "Criteria": "Treatment of HER2 positive breast cancer in combination with trastuzumab",
            "Website": "http://www.pbs.gov.au/pbs/search?term=Paclitaxel NAB&search-type=medicines&analyse=false"
      },
        {
            "ID": "328",
            "DrugID": "022",
            "Drug": "Paclitaxel NAB",
            "Strength": "",
            "PBSCode": "10150F",
            "Streamline": "4657",
            "PBSQty": "275",
            "PBSRepeats": "11",
            "Category": "IN",
            "Restriction": "A",
            "Type": "Private",
            "Route": "Injectable",
            "ScriptType": "Streamline Authority",
            "Diagnosis": "Stage IV (metastatic) adenocarcinoma of the pancreas",
            "Treatment": "",
            "Criteria": "The treatment must be in combination with gemcitabine, AND The condition must not have been treated previously with PBS-subsidised therapy, AND Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status score of 2 or less. A patient who has progressive disease when treated with this drug is no longer eligible for PBS-subsidised treatment with this drug.",
            "Website": "http://www.pbs.gov.au/pbs/search?term=Paclitaxel NAB&search-type=medicines&analyse=false"
      },
        {
            "ID": "340",
            "DrugID": "024",
            "Drug": "Panitumumab",
            "Strength": "",
            "PBSCode": "10069Y",
            "Streamline": "4783",
            "PBSQty": "720",
            "PBSRepeats": "5",
            "Category": "IN",
            "Restriction": "A",
            "Type": "Private",
            "Route": "Injectable",
            "ScriptType": "Streamline Authority",
            "Diagnosis": "Metastatic colorectal cancer",
            "Treatment": "Continuing treatment",
            "Criteria": "Patient must have received an initial authority prescription for this drug for treatment of RAS wild-type metastatic colorectal cancer after failure of first-line chemotherapy, AND Patient must not have progressive disease, AND The treatment must be as monotherapy; OR The treatment must be in combination with an irinotecan based therapy, AND The treatment must be the sole PBS-subsidised anti-EGFR antibody therapy for this condition. Patients who have progressive disease on cetuximab are not eligible to receive PBS-subsidised panitumumab. Patients who have developed intolerance to cetuximab of a severity necessitating permanent treatment withdrawal are eligible to receive PBS-subsidised panitumumab.",
            "Website": "http://www.pbs.gov.au/pbs/search?term=Panitumumab&search-type=medicines&analyse=false"
      },
        {
            "ID": "342",
            "DrugID": "024",
            "Drug": "Panitumumab",
            "Strength": "",
            "PBSCode": "10069Y",
            "Streamline": "4784",
            "PBSQty": "720",
            "PBSRepeats": "5",
            "Category": "IN",
            "Restriction": "A",
            "Type": "Private",
            "Route": "Injectable",
            "ScriptType": "Streamline Authority",
            "Diagnosis": "Metastatic colorectal cancer",
            "Treatment": "Failed to respond to first-line chemotherapy",
            "Criteria": "Patient must have RAS wild-type metastatic colorectal cancer, AND Patient must have a WHO performance status of 2 or less, AND The condition must have failed to respond to first-line chemotherapy, AND The treatment must be as monotherapy; OR The treatment must be in combination with an irinotecan based therapy, AND The treatment must be the sole PBS-subsidised anti-EGFR antibody therapy for this condition. Patients who have progressive disease on cetuximab are not eligible to receive PBS-subsidised panitumumab. Patients who have developed intolerance to cetuximab of a severity necessitating permanent treatment withdrawal are eligible to receive PBS-subsidised panitumumab.",
            "Website": "http://www.pbs.gov.au/pbs/search?term=Panitumumab&search-type=medicines&analyse=false"
      },
        {
            "ID": "360",
            "DrugID": "026",
            "Drug": "Pemetrexed",
            "Strength": "",
            "PBSCode": "7255W",
            "Streamline": "4789",
            "PBSQty": "1100",
            "PBSRepeats": "5",
            "Category": "IN",
            "Restriction": "A",
            "Type": "Private",
            "Route": "Injectable",
            "ScriptType": "Streamline Authority",
            "Diagnosis": "Mesothelioma",
            "Treatment": "",
            "Criteria": "MThe treatment must be in combination with cisplatin. The patient's body surface area (BSA) must be documented in the patient's medical records at the time the treatment cycle is initiated Doses greater than 500 mg per metre squared BSA are not PBS-subsidised",
            "Website": "http://www.pbs.gov.au/pbs/search?term=Pemetrexed&search-type=medicines&analyse=false"
      },
        {
            "ID": "362",
            "DrugID": "026",
            "Drug": "Pemetrexed",
            "Strength": "",
            "PBSCode": "7255W",
            "Streamline": "4792",
            "PBSQty": "1100",
            "PBSRepeats": "5",
            "Category": "IN",
            "Restriction": "A",
            "Type": "Private",
            "Route": "Injectable",
            "ScriptType": "Streamline Authority",
            "Diagnosis": "Non-small cell lung cancer",
            "Treatment": "",
            "Criteria": "Patient must have received prior treatment with platinum-based chemotherapy. The patient's body surface area (BSA) must be documented in the patient's medical records at the time the treatment cycle is initiated Doses greater than 500 mg per metre squared BSA are not PBS-subsidised",
            "Website": "http://www.pbs.gov.au/pbs/search?term=Pemetrexed&search-type=medicines&analyse=false"
      },
        {
            "ID": "364",
            "DrugID": "027",
            "Drug": "Rituximab",
            "Strength": "",
            "PBSCode": "10193L",
            "Streamline": "4674",
            "PBSQty": "800",
            "PBSRepeats": "11",
            "Category": "IN",
            "Restriction": "A",
            "Type": "Private",
            "Route": "Injectable",
            "ScriptType": "Streamline Authority",
            "Diagnosis": "B-cell non-Hodgkin's lymphoma",
            "Treatment": "Maintenance therapy",
            "Criteria": "Patient must have demonstrated a partial or complete response to the induction phase of treatment for previously untreated follicular B-cell Non-Hodgkin's lymphoma, received immediately prior to this current Authority application, AND The treatment must be maintenance therapy, AND Patient must not receive more than 12 doses or 2 years duration of treatment, whichever comes first, under this restriction.",
            "Website": "http://www.pbs.gov.au/pbs/search?term=Rituximab&search-type=medicines&analyse=false"
      },
        {
            "ID": "366",
            "DrugID": "027",
            "Drug": "Rituximab",
            "Strength": "",
            "PBSCode": "7257Y",
            "Streamline": "4677",
            "PBSQty": "800",
            "PBSRepeats": "3",
            "Category": "IN",
            "Restriction": "A",
            "Type": "Private",
            "Route": "Injectable",
            "ScriptType": "Streamline Authority",
            "Diagnosis": "Relapsed or refractory low-grade B-cell non-Hodgkin's lymphoma",
            "Treatment": "Re-induction treatment",
            "Criteria": "The treatment must be for re-induction treatment purposes only, AND The condition must have relapsed or be refractory to treatment, AND Patient must not receive more than 4 doses under this restriction.",
            "Website": "http://www.pbs.gov.au/pbs/search?term=Rituximab&search-type=medicines&analyse=false"
      },
        {
            "ID": "368",
            "DrugID": "027",
            "Drug": "Rituximab",
            "Strength": "",
            "PBSCode": "7257Y",
            "Streamline": "4678",
            "PBSQty": "800",
            "PBSRepeats": "3",
            "Category": "IN",
            "Restriction": "A",
            "Type": "Private",
            "Route": "Injectable",
            "ScriptType": "Streamline Authority",
            "Diagnosis": "Relapsed or refractory follicular B-cell non-Hodgkin's lymphoma",
            "Treatment": "Re-induction treatment",
            "Criteria": "The treatment must be for re-induction treatment purposes only, AND The condition must have relapsed or be refractory to treatment, AND Patient must not receive more than 4 doses under this restriction.",
            "Website": "http://www.pbs.gov.au/pbs/search?term=Rituximab&search-type=medicines&analyse=false"
      },
        {
            "ID": "370",
            "DrugID": "027",
            "Drug": "Rituximab",
            "Strength": "",
            "PBSCode": "7258B",
            "Streamline": "4686",
            "PBSQty": "800",
            "PBSRepeats": "7",
            "Category": "IN",
            "Restriction": "A",
            "Type": "Private",
            "Route": "Injectable",
            "ScriptType": "Streamline Authority",
            "Diagnosis": "Relapsed or refractory Stage III or IV CD20 positive follicular B-cell non-Hodgkin's lymphoma",
            "Treatment": "Maintenance therapy",
            "Criteria": "Relapsed or refractory The treatment must be maintenance therapy, AND Patient must have demonstrated a partial or complete response to re-induction treatment received immediately prior to this current Authority application, AND Patient must not receive more than 8 cycles or 2 years duration of treatment, whichever comes first, under this restriction.",
            "Website": "http://www.pbs.gov.au/pbs/search?term=Rituximab&search-type=medicines&analyse=false"
      },
        {
            "ID": "372",
            "DrugID": "027",
            "Drug": "Rituximab",
            "Strength": "",
            "PBSCode": "7258B",
            "Streamline": "4701",
            "PBSQty": "800",
            "PBSRepeats": "7",
            "Category": "IN",
            "Restriction": "A",
            "Type": "Private",
            "Route": "Injectable",
            "ScriptType": "Streamline Authority",
            "Diagnosis": "Large B-cell non-Hodgkin's lymphoma",
            "Treatment": "Induction treatment",
            "Criteria": "The treatment must be in combination with chemotherapy, AND The condition must be previously untreated, AND The condition must be symptomatic, AND The treatment must be for induction treatment purposes only, AND Patient must not receive more than 8 doses under this restriction.",
            "Website": "http://www.pbs.gov.au/pbs/search?term=Rituximab&search-type=medicines&analyse=false"
      },
        {
            "ID": "374",
            "DrugID": "027",
            "Drug": "Rituximab",
            "Strength": "",
            "PBSCode": "7259C",
            "Streamline": "4706",
            "PBSQty": "1100",
            "PBSRepeats": "5",
            "Category": "IN",
            "Restriction": "A",
            "Type": "Private",
            "Route": "Injectable",
            "ScriptType": "Streamline Authority",
            "Diagnosis": "Chronic lymphocytic leukaemia (CLL)",
            "Treatment": "",
            "Criteria": "The condition must be CD20 positive chronic lymphocytic leukaemia (CLL), AND The treatment must be in combination with chemotherapy.",
            "Website": "http://www.pbs.gov.au/pbs/search?term=Rituximab&search-type=medicines&analyse=false"
      },
        {
            "ID": "376",
            "DrugID": "027",
            "Drug": "Rituximab",
            "Strength": "",
            "PBSCode": "7258B",
            "Streamline": "4726",
            "PBSQty": "800",
            "PBSRepeats": "7",
            "Category": "IN",
            "Restriction": "A",
            "Type": "Private",
            "Route": "Injectable",
            "ScriptType": "Streamline Authority",
            "Diagnosis": "B-cell non-Hodgkin's lymphoma",
            "Treatment": "Induction treatment",
            "Criteria": "The treatment must be in combination with chemotherapy, AND The condition must be previously untreated, AND The condition must be symptomatic, AND The treatment must be for induction treatment purposes only, AND Patient must not receive more than 8 doses under this restriction.",
            "Website": "http://www.pbs.gov.au/pbs/search?term=Rituximab&search-type=medicines&analyse=false"
      },
        {
            "ID": "377",
            "DrugID": "028",
            "Drug": "Sorafenib",
            "Strength": "200mg",
            "PBSCode": "9380Q",
            "Streamline": "4230",
            "PBSQty": "120",
            "PBSRepeats": "2",
            "Category": "GE",
            "Restriction": "A",
            "Type": "General",
            "Route": "Oral",
            "ScriptType": "Streamline Authority",
            "Diagnosis": "Liver Cancer",
            "Treatment": "Initial treatment",
            "Criteria": "The treatment must be the sole PBS-subsidised therapy for this condition, AND Patient must have a WHO performance status of 2 or less, AND Patient must have Child Pugh class A.",
            "Website": "http://www.pbs.gov.au/pbs/search?term=Sorafenib&search-type=medicines&analyse=false"
      },
        {
            "ID": "378",
            "DrugID": "028",
            "Drug": "Sorafenib",
            "Strength": "200mg",
            "PBSCode": "9380Q",
            "Streamline": "4234",
            "PBSQty": "120",
            "PBSRepeats": "2",
            "Category": "GE",
            "Restriction": "A",
            "Type": "General",
            "Route": "Oral",
            "ScriptType": "Streamline Authority",
            "Diagnosis": "Liver Cancer",
            "Treatment": "Continuing treatment",
            "Criteria": "The treatment must be the sole PBS-subsidised therapy for this condition, AND Patient must have previously been treated with PBS-subsidised sorafenib, AND Patient must not have progressive disease.",
            "Website": "http://www.pbs.gov.au/pbs/search?term=Sorafenib&search-type=medicines&analyse=false"
      },
        {
            "ID": "382",
            "DrugID": "030",
            "Drug": "Topotecan",
            "Strength": "",
            "PBSCode": "7260D",
            "Streamline": "3186",
            "PBSQty": "3500",
            "PBSRepeats": "17",
            "Category": "IN",
            "Restriction": "A",
            "Type": "Private",
            "Route": "Injectable",
            "ScriptType": "Streamline Authority",
            "Diagnosis": "Advanced metastatic ovarian cancer",
            "Treatment": "",
            "Criteria": "Advanced metastatic ovarian cancer after failure of prior therapy which includes a platinum compound",
            "Website": "http://www.pbs.gov.au/pbs/search?term=Topotecan&search-type=medicines&analyse=false"
      },
        {
            "ID": "387",
            "DrugID": "031",
            "Drug": "Zoledronic Acid",
            "Strength": "",
            "PBSCode": "9350D",
            "Streamline": "4876",
            "PBSQty": "1",
            "PBSRepeats": "0",
            "Category": "GE",
            "Restriction": "A",
            "Type": "General",
            "Route": "Injectable",
            "ScriptType": "Streamline Authority",
            "Diagnosis": "Symptomatic Paget disease of bone",
            "Treatment": "",
            "Criteria": "Symptomatic Paget disease of bone Only 1 treatment each year per patient will be PBS-subsidised",
            "Website": "http://www.pbs.gov.au/pbs/search?term=Zoledronic Acid&search-type=medicines&analyse=false"
      }
    ]
